DE602006020347D1 - Zusammensetzungen und verfahren zur oxalatreduktion - Google Patents

Zusammensetzungen und verfahren zur oxalatreduktion

Info

Publication number
DE602006020347D1
DE602006020347D1 DE200660020347 DE602006020347T DE602006020347D1 DE 602006020347 D1 DE602006020347 D1 DE 602006020347D1 DE 200660020347 DE200660020347 DE 200660020347 DE 602006020347 T DE602006020347 T DE 602006020347T DE 602006020347 D1 DE602006020347 D1 DE 602006020347D1
Authority
DE
Germany
Prior art keywords
compositions
oxalate
hyperoxaluria
methods
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE200660020347
Other languages
German (de)
English (en)
Inventor
Qingshan Li
Harmeet Sidhu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxthera Inc
Original Assignee
Oxthera Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxthera Inc filed Critical Oxthera Inc
Publication of DE602006020347D1 publication Critical patent/DE602006020347D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/488—Aspartic endopeptidases (3.4.23), e.g. pepsin, chymosin, renin, cathepsin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51—Lyases (4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y102/00—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2)
    • C12Y102/03—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2) with oxygen as acceptor (1.2.3)
    • C12Y102/03004—Oxalate oxidase (1.2.3.4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y208/00—Transferases transferring sulfur-containing groups (2.8)
    • C12Y208/03—CoA-transferases (2.8.3)
    • C12Y208/03016—Formyl-CoA transferase (2.8.3.16)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/23—Aspartic endopeptidases (3.4.23)
    • C12Y304/23002—Pepsin B (3.4.23.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y401/00—Carbon-carbon lyases (4.1)
    • C12Y401/01—Carboxy-lyases (4.1.1)
    • C12Y401/01002—Oxalate decarboxylase (4.1.1.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y401/00—Carbon-carbon lyases (4.1)
    • C12Y401/01—Carboxy-lyases (4.1.1)
    • C12Y401/01008—Oxalyl-CoA decarboxylase (4.1.1.8)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5115—Inorganic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE200660020347 2005-12-16 2006-12-15 Zusammensetzungen und verfahren zur oxalatreduktion Active DE602006020347D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75089605P 2005-12-16 2005-12-16
PCT/US2006/047967 WO2007075447A2 (en) 2005-12-16 2006-12-15 Compositions and methods for oxalate reduction

Publications (1)

Publication Number Publication Date
DE602006020347D1 true DE602006020347D1 (de) 2011-04-07

Family

ID=38218470

Family Applications (1)

Application Number Title Priority Date Filing Date
DE200660020347 Active DE602006020347D1 (de) 2005-12-16 2006-12-15 Zusammensetzungen und verfahren zur oxalatreduktion

Country Status (11)

Country Link
US (2) US8900575B2 (enExample)
EP (2) EP1976553B1 (enExample)
JP (1) JP5558002B2 (enExample)
CN (3) CN107638563A (enExample)
AT (1) ATE499111T1 (enExample)
AU (1) AU2006329844B2 (enExample)
CA (1) CA2633238A1 (enExample)
DE (1) DE602006020347D1 (enExample)
ES (1) ES2362897T3 (enExample)
HK (1) HK1201151A1 (enExample)
WO (1) WO2007075447A2 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8486389B2 (en) 1997-05-23 2013-07-16 Oxthera, Inc. Compositions and methods for treating or preventing oxalate-related disease
JP5558002B2 (ja) 2005-12-16 2014-07-23 オクセラ インコーポレイテッド シュウ酸塩低減化のための組成物および方法
DK2046373T3 (da) 2006-08-02 2013-05-27 Althea Technologies Inc Krystalliseret oxalatdecarboxylase og fremgangsmåder til anvendelse
CN101554237B (zh) * 2009-03-16 2013-11-06 武汉康复得生物科技有限公司 植物纤维或微生物不溶组分中的草酸降解酶的制备方法
US8431122B2 (en) 2009-07-02 2013-04-30 Oxthera Intellectual Property Ab Purification and isolation of recombinant oxalate degrading enzymes and spray-dried particles containing oxalate degrading enzymes
ES2617917T3 (es) 2009-07-02 2017-06-20 Oxthera Intellectual Property Ab Purificación y aislamiento de enzimas de degradación de oxalato recombinantes y partículas secadas por atomización que contienen enzimas de degradación de oxalato
DK2270138T3 (en) * 2009-07-02 2018-06-25 Oxthera Intellectual Property Ab Purification and isolation of recombinant oxalate-degrading enzymes
WO2011066282A2 (en) * 2009-11-25 2011-06-03 Captozyme, Llc Methods and compositions for treating oxalate-related conditions
US9878020B2 (en) * 2011-04-07 2018-01-30 Histapharm Inc. Oral enzyme compositions for intestinal delivery
WO2014113648A1 (en) 2013-01-18 2014-07-24 Allena Pharmaceuticals, Inc. Crystallized oxalate decarboxylase and methods of use
US11077238B2 (en) 2013-06-07 2021-08-03 Allena Pharmaceuticals, Inc. Compositions, methods, and devices for dialysis
AU2016244121B2 (en) * 2015-04-02 2020-11-05 Orenzymes Llc High efficiency oxalate-degrading enzymes for degradation of insoluble and soluble oxalate
CA3023042A1 (en) 2016-06-13 2017-12-21 Oxthera Intellectual Property Ab Compositions and methods for the treatment or prevention of oxalate-related disorders
EP3707202A1 (en) 2017-11-08 2020-09-16 Materias S.r.l. In situ gelifying powder
CN114903985A (zh) * 2021-02-10 2022-08-16 宁波倍益嘉生物科技有限公司 一种组合物及其在防治高草酸尿症方面的应用
AU2022341115A1 (en) * 2021-09-09 2024-04-11 Unlocked Labs Inc. Therapeutic engineered microbial cell systems and methods for treating conditions in which oxalate is detrimental
CN116444636B (zh) * 2023-04-17 2024-02-20 西南大学 抑制核盘菌的水稻OsGLP3-6及其应用

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4205132A (en) 1978-07-17 1980-05-27 Microlife Technics, Inc. Lyophilization of bacteria
DE3030185A1 (de) 1980-08-07 1982-04-08 Kohlbecker, Günther, 3000 Hannover Verfahren zur enzymatischen entfernung von oxalat mittels oxalat-oxidase
DE3204284A1 (de) 1982-02-06 1983-08-18 Kohlbecker, Günther, 3000 Hannover Verfahren zur enzymatischen entfernung von sauerstoff
JPS5968344A (ja) 1982-10-12 1984-04-18 Agency Of Ind Science & Technol 非対称機能膜及びその製法
US4539118A (en) 1984-03-23 1985-09-03 Sigma Chemical Company Rapid, accurate method of separation of oxalate from urine and other biological fluids
US5263992A (en) 1986-10-17 1993-11-23 Bio-Metric Systems, Inc. Biocompatible device with covalently bonded biocompatible agent
US5427935A (en) * 1987-07-24 1995-06-27 The Regents Of The University Of Michigan Hybrid membrane bead and process for encapsulating materials in semi-permeable hybrid membranes
US5206219A (en) 1991-11-25 1993-04-27 Applied Analytical Industries, Inc. Oral compositions of proteinaceous medicaments
US5286495A (en) * 1992-05-11 1994-02-15 University Of Florida Process for microencapsulating cells
EP0673416A1 (en) 1992-11-30 1995-09-27 Zeneca Limited Oxalate decarboxylase
FI954911A0 (fi) 1993-04-16 1995-10-16 Mccormick & Co Inc Kapselointikoostumukset
US5554147A (en) 1994-02-01 1996-09-10 Caphco, Inc. Compositions and devices for controlled release of active ingredients
US5788687A (en) 1994-02-01 1998-08-04 Caphco, Inc Compositions and devices for controlled release of active ingredients
US5505713A (en) 1994-04-01 1996-04-09 Minimed Inc. Indwelling catheter with stable enzyme coating
JPH10500019A (ja) 1994-05-18 1998-01-06 ヒューマン・ジェノム・サイエンシズ・インコーポレイテッド ヒトのオキサリル−ＣｏＡデカルボキシラーゼ
US6090628A (en) 1994-06-20 2000-07-18 University Of Florida Materials and methods for detection of Oxalobactor formigenes
US5912125A (en) 1994-06-20 1999-06-15 University Of Florida Materials and methods for detection of oxalobacter
US5604111A (en) 1994-06-20 1997-02-18 University Of Florida Research Foundation Method and kit for detection of oxalate
US6214980B1 (en) 1994-06-20 2001-04-10 University Of Florida Materials and methods for detection of Oxalobacte formigenes
US5916790A (en) * 1995-03-03 1999-06-29 Metabolex, Inc. Encapsulation compositions, and methods
US6033719A (en) 1996-04-25 2000-03-07 Medtronic, Inc. Method for covalent attachment of biomolecules to surfaces of medical devices
SE9603029D0 (sv) 1996-08-20 1996-08-20 Svenska Traeforskningsinst Method for lowering the level of oxalic acid
US7435425B2 (en) * 2001-07-17 2008-10-14 Baxter International, Inc. Dry hemostatic compositions and methods for their preparation
JP4335316B2 (ja) * 1996-09-19 2009-09-30 ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミシガン アルギネートまたは修飾アルギネートのようなポリサッカライドを含むポリマー
US6297425B1 (en) 1997-03-21 2001-10-02 Pioneer Hi-Bred International, Inc. Gene encoding oxalate decarboxylase from aspergillus phoenices
DE69841200D1 (de) 1997-05-23 2009-11-12 Oxthera Inc Oxalate-abbauende mikroorganismen oder oxalate-abbauende enzyme zur verhütung der oxalate-verwandten krankheiten
US20040120941A1 (en) * 1997-05-23 2004-06-24 Allison Milton J. Materials and methods for treating or preventing oxalate-related disease
US6355242B1 (en) 1997-05-23 2002-03-12 Ixion Biotechnology, Inc. Materials and methods for treating or preventing oxalate-related disease
US8486389B2 (en) 1997-05-23 2013-07-16 Oxthera, Inc. Compositions and methods for treating or preventing oxalate-related disease
US6161499A (en) * 1997-07-07 2000-12-19 Cvd Diamond Corporation Apparatus and method for nucleation and deposition of diamond using hot-filament DC plasma
US6080404A (en) 1997-09-05 2000-06-27 University Of Florida Materials and methods for removal of substances from fluids
US5985938A (en) 1997-11-05 1999-11-16 Geltex Pharmaceuticals, Inc. Method for reducing oxalate
US6566407B2 (en) 1997-11-05 2003-05-20 Geltex Pharmaceuticals, Inc. Method for reducing oxalate
US6203797B1 (en) 1998-01-06 2001-03-20 Stephen C. Perry Dietary supplement and method for use as a probiotic, for alleviating the symptons associated with irritable bowel syndrome
WO1999055878A1 (en) * 1998-04-24 1999-11-04 Onyx Pharmaceuticals, Inc. Novel nucleic acids and polypeptides related to a farnesyl-directed cysteine carboxymethyltransferase
MXPA01003197A (es) 1998-09-28 2004-04-21 Warner Lambert Co Suministro enterico y colonico utilizando capsulas de chpm.
DE69940821D1 (de) 1998-10-09 2009-06-10 Gen Mills Inc Verkapselung empfindlicher flüssiger komponenten in eine matrix zur gewinnung diskreter lagerbeständiger partikel
IT1309427B1 (it) 1999-05-28 2002-01-23 Mendes S U R L Composizione dietetica o farmaceutica utile per la prevenzione o iltrattamento dell'iperossaluria e suo uso
HK1046098A1 (zh) 1999-06-07 2002-12-27 南诺斯菲尔股份有限公司 包被颗粒的方法以及所得颗粒
ATE391509T1 (de) 2000-12-18 2008-04-15 Probio Health Von lactobacillus casei ke01 stamm abgeleitete probiotische verbindungen
US7407668B2 (en) 2002-01-24 2008-08-05 Boston Scimed, Inc. Medical articles having enzymatic surfaces for localized therapy
US6929940B1 (en) 2002-08-20 2005-08-16 University Of Florida Research Foundation, Inc. Polynucleotides encoding oxalate decarboxylase from Aspergillus niger and methods of use
NL1021879C2 (nl) * 2002-11-08 2004-05-11 Univ Delft Tech Werkwijze voor het bereiden van vernette enzymdeeltjes.
WO2005060937A1 (en) 2003-12-23 2005-07-07 Chr. Hansen A/S Compressed tablets comprising viable probiotic microorganisms
WO2005110469A2 (en) * 2004-05-07 2005-11-24 Oxthera, Inc. Methods and compositions for reducing oxalate concentrations
AU2005339139A1 (en) 2005-12-14 2007-06-21 Oxthera, Inc. Pharmaceutical compositions and methods for treating or preventing oxalate-related disease
JP5558002B2 (ja) 2005-12-16 2014-07-23 オクセラ インコーポレイテッド シュウ酸塩低減化のための組成物および方法
DK2046373T3 (da) 2006-08-02 2013-05-27 Althea Technologies Inc Krystalliseret oxalatdecarboxylase og fremgangsmåder til anvendelse
US8431122B2 (en) 2009-07-02 2013-04-30 Oxthera Intellectual Property Ab Purification and isolation of recombinant oxalate degrading enzymes and spray-dried particles containing oxalate degrading enzymes

Also Published As

Publication number Publication date
HK1128613A1 (en) 2009-11-06
CN104013581A (zh) 2014-09-03
EP1976553A2 (en) 2008-10-08
AU2006329844A1 (en) 2007-07-05
WO2007075447A3 (en) 2008-12-24
CN107638563A (zh) 2018-01-30
EP1976553B1 (en) 2011-02-23
US20150125538A1 (en) 2015-05-07
AU2006329844A8 (en) 2008-07-31
AU2006329844B2 (en) 2012-11-15
WO2007075447A2 (en) 2007-07-05
US8900575B2 (en) 2014-12-02
EP1976553A4 (en) 2009-09-23
CN101405022A (zh) 2009-04-08
ATE499111T1 (de) 2011-03-15
CA2633238A1 (en) 2007-07-05
HK1201151A1 (en) 2015-08-28
US20070184118A1 (en) 2007-08-09
ES2362897T3 (es) 2011-07-14
EP2366402A1 (en) 2011-09-21
US10272043B2 (en) 2019-04-30
JP5558002B2 (ja) 2014-07-23
JP2009519950A (ja) 2009-05-21

Similar Documents

Publication Publication Date Title
ATE499111T1 (de) Zusammensetzungen und verfahren zur oxalatreduktion
PT1773361E (pt) Composição baseada em bactérias probióticas e sua utilização na prevenção e/ou tratamento de patologias e/ou infecções respiratórias e na melhoria da funcionalidade intestinal
ZA200801706B (en) Methods and compositions for the prevention and treatment of kidney disease
EP2047863A4 (en) MEANS FOR THE PREVENTION OR TREATMENT OF INFLAMMATORY DISEASES
BRPI0616960B8 (pt) uso de lactobacilo para o tratamento de infecções virais
BRPI0717219A2 (pt) "composição imunogênica, método para tratar ou prevenir doença, e, uso de uma composição imunogênica."
MA30250B1 (fr) Vaccins destines a lutter contre une infection a chlamydia
WO2008043107A3 (en) Use of tight junction antagonists to treat inflammatory bowel disease
BRPI0807046A2 (pt) Composto, composição farmacêutica, métodos de tratar um distúrbio, uma doença cardiovascular e um paciente que sofre de motilidade gastrointestinal reduzida ou disfuncional e, kit.
BRPI0711901A2 (pt) Composições e métodos para a liberação de oxigênio
ZA200800452B (en) Methods and compositions for the prevention and treatment of kidney disease
MX2009006760A (es) Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedades meningococicas.
BRPI0817063A2 (pt) "métodos de inibição, para o tratamento de uma condição patológica, para a inibição de linfagiogênese tumoral, de inibição ou prevenção,de desorganização, para inibição de crescimento de tumor, de tratamento, de acentuação da eficácia de um agente anti-angiogênese e antagonista de alk-1
BRPI0817905A2 (pt) Utilização de uma cepa de bifidobacterium, para o preparo de uma composição destinada à prevenção e/ou ao tratamento de manifestações do tipo alérgicas
WO2010115092A3 (en) Compositions and methods for treating or preventing inflammatory bowel disease and colon cancer
CL2007003332A1 (es) Compuestos derivados de heterociclos condensados; compuestos intermediarios; composicion farmaceutica; y uso en la prevencion o tratamiento de infecciones bacterianas.
EP2651439A4 (en) COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING HUMAN ADENOVIRUS 36 INFECTION
IL189270A0 (en) Phosphonated rifamycins and uses thereof for the prevention and treatment of bone and joint infections
WO2008088524A3 (en) Thrombospondin-domain-deficient r-spondin 1 protein as gastrointestinal tract epithelial proliferation factor
EP2388317A4 (en) GENE ENCODING A MUTANT OF HUMAN GLUCOKINASE, ENZYME CODED THEREOF, RECOMBINANT VECTORS AND RECOMBINANT HOSTS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF, METHODS OF TREATMENT AND PREVENTION OF DISEASES
WO2009114461A3 (en) Angiotensin (1-7) dosage forms and uses thereof
ATE546149T1 (de) Prävention und behandlung von allergischer diarrhöe
EP2076284A4 (en) METHOD FOR THE TREATMENT, PREVENTION AND DIAGNOSIS OF TTV INFECTION IN PIGS
EP2666480A3 (en) Uses and compositions for treatment of Crohn's desease
WO2009042642A3 (en) Compositions and methods for the treatment and prevention of ulcerative colitis and colon cancer